CN118027033A - HDAC6 inhibitor, preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis - Google Patents
HDAC6 inhibitor, preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis Download PDFInfo
- Publication number
- CN118027033A CN118027033A CN202410113655.3A CN202410113655A CN118027033A CN 118027033 A CN118027033 A CN 118027033A CN 202410113655 A CN202410113655 A CN 202410113655A CN 118027033 A CN118027033 A CN 118027033A
- Authority
- CN
- China
- Prior art keywords
- hdac6 inhibitor
- hdac6
- inhibitor according
- hydroxylamine
- ulcerative colitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022537 Histone deacetylase 6 Human genes 0.000 title claims abstract description 65
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 title claims abstract description 64
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 239000003112 inhibitor Substances 0.000 title claims abstract description 56
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 21
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 21
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 16
- 150000003797 alkaloid derivatives Chemical group 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 22
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 claims description 17
- 229930017327 cytisine Natural products 0.000 claims description 17
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 claims description 17
- 229940027564 cytisine Drugs 0.000 claims description 17
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 13
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 12
- CEIXWJHURKEBMQ-UHFFFAOYSA-N Heliamine Chemical compound C1CNCC2=C1C=C(OC)C(OC)=C2 CEIXWJHURKEBMQ-UHFFFAOYSA-N 0.000 claims description 12
- 229930013930 alkaloid Natural products 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical compound C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 claims description 6
- ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 claims description 5
- GDALETGZDYOOGB-UHFFFAOYSA-N Acridone Natural products C1=C(O)C=C2N(C)C3=CC=CC=C3C(=O)C2=C1O GDALETGZDYOOGB-UHFFFAOYSA-N 0.000 claims description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 5
- FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 claims description 5
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 claims description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229940114081 cinnamate Drugs 0.000 claims description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 4
- 230000000767 anti-ulcer Effects 0.000 abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 10
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 239000001993 wax Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- -1 alkaloid compounds Chemical class 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000009266 disease activity Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 4
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004012 Tofacitinib Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 3
- 229960001350 tofacitinib Drugs 0.000 description 3
- XXUWLTLDLPHNND-MDZDMXLPSA-N (E)-3-[4-(2,3-dihydroindol-1-ylmethyl)phenyl]-N-hydroxyprop-2-enamide Chemical compound N1(CCC2=CC=CC=C12)CC1=CC=C(C=C1)/C=C/C(=O)NO XXUWLTLDLPHNND-MDZDMXLPSA-N 0.000 description 2
- YNCVWQWRUHJBEL-MDZDMXLPSA-N (e)-3-[4-(3,4-dihydro-1h-isoquinolin-2-ylmethyl)phenyl]-n-hydroxyprop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NO)=CC=C1CN1CC2=CC=CC=C2CC1 YNCVWQWRUHJBEL-MDZDMXLPSA-N 0.000 description 2
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UVDDFTZLVFIQFL-VOTSOKGWSA-N (e)-n-hydroxy-3-phenylprop-2-enamide Chemical group ONC(=O)\C=C\C1=CC=CC=C1 UVDDFTZLVFIQFL-VOTSOKGWSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
- 108010023925 Histone Deacetylase 6 Proteins 0.000 description 1
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- ZSRCGGBALFGALF-UHFFFAOYSA-N methyl 3-[4-(bromomethyl)phenyl]prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(CBr)C=C1 ZSRCGGBALFGALF-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- SFSSMGSFESHVQM-UHFFFAOYSA-N n-hydroxy-4-methylbenzamide Chemical group CC1=CC=C(C(=O)NO)C=C1 SFSSMGSFESHVQM-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an HDAC6 inhibitor, a preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis, wherein a series of novel compounds containing alkaloid structures and having anti-ulcerative colitis activity are developed by connecting an alkaloid structure with a hydroxamic acid group of the HDAC6 inhibitor, experimental data show that the compounds have better inhibition effect on the HDAC6 at enzyme level, and can be used for preparing medicines for preventing or treating ulcerative colitis.
Description
The invention belongs to the technical field of drug synthesis, and particularly relates to an HDAC6 inhibitor, a preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis.
Background
Ulcerative colitis (Ulcerative colitis, UC) is a chronic, nonspecific inflammation of the rectum and colon, with a long course of disease, which is difficult to heal. The disease is seen in European and American regions, and the incidence rate in China has an increasing trend in recent years. Since the etiology and pathogenesis of UC are not yet fully elucidated, there is currently no specific drug.
Histone deacetylase 6 (Histone deacetylase) is an important member of the class IIb HDAC family, and is involved in important physiological processes such as regulation of cell growth, metastasis and apoptosis by modification of specific substrates including α -tubulin and heat shock protein 90 (HSP 90). Studies show that the over-expression of HDAC6 can increase the level of alpha-tubulin in a dose-dependent manner, further up-regulate the expression of NADPH oxidase and induce the generation of Reactive Oxygen Species (ROS), so as to reduce the level of NF- κB related proteins such as IKKα/β and IκB, and finally lead to the increase of the levels of pro-inflammatory factors such as TNF- α, IL-1β and IL-6. Currently, HDAC6 is gaining increasing attention in the research related to inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis and chronic asthma. The selective HDAC6 inhibitor gradually becomes a research hot spot because of being basically nontoxic to normal cells, and the design and development of a novel selective HDAC6 inhibitor for inflammatory diseases have important social value.
The pharmacophore model for selective HDAC6 inhibitors is largely divided into three parts: zinc ion chelating group (ZBG), linker occupying hydrophobic channel (linker), active pocket surface recognition region (Cap). The affinity of HDAC6 inhibitors for different subtypes generally depends on the interaction and geometric conformation of the above three moieties with the active site. Among these, the Cap group, which has the greatest effect on activity, is often located in the surface portion of the protein, and interacts with the edge region outside the pocket. Linker moiety is occupied in the channel of the protein, and plays a role in supporting and linking the stabilization of the whole molecular conformation. The ZBG group is generally located inside a protein pocket and forms a chelate with Zn 2+ and other amino acid residues in the protein, and HDAC6 inhibitors can be classified into hydroxamic acids, benzamides and fatty carboxylic acids according to the ZBG structure, wherein the hydroxamic acids are most widely used, such as vorinostat (SAHA), bei Lisi he (PXD 101) and panobinostat (LBH 589), etc.
Despite the significant progress in the current research of selective HDAC6 inhibitors, most are in the clinical trial stage and there are no approved drugs on the market. At present, the specific mechanism of the HDAC6 inhibitor in the aspect of participating in inflammation is not completely elucidated, and most candidate drugs have the problems of poor pharmacokinetics, unstable metabolism and the like, so that the further development of the candidate drugs is restricted.
Disclosure of Invention
In order to solve the problems, the invention provides an HDAC6 inhibitor, a preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis. The invention connects the alkaloid structure with anti-inflammatory activity with the hydroxamic acid group of the HDAC6 inhibitor through the design of computer-aided drugs and the framework transition principle, and develops a novel HDAC6 inhibitor with anti-ulcerative colitis activity containing the alkaloid structure.
The technical scheme of the invention is as follows:
an HDAC6 inhibitor having the structure:
R is at least one substituent selected from cytisine, acridone, indoline, 1,2,3, 4-tetrahydro-9H-pyridine [3,4-B ] benzidine, 1,2,3, 4-tetrahydroisoquinoline, 6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinoline, 5-aminoindole, 2-hydroxyquinoxaline, 2-hydroxyquinoline and the like;
x is a saturated or unsaturated alkane containing from 0 to 4 carbon atoms.
Further preferred are the HDAC6 inhibitors of formula I or formula II, which are specifically represented by the following structures:
;
wherein R1 and R2 are respectively and independently selected from at least one of cytisine, acridone, indoline, 1,2,3, 4-tetrahydro-9H-pyridine [3,4-B ] indole, 1,2,3, 4-tetrahydroisoquinoline, 6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinoline, 5-aminoindole, 2-hydroxyquinoxaline and 2-hydroxyquinoline.
It is further preferred that the structure of the HDAC6 inhibitor is any one of the following:
a method of preparing the HDAC6 inhibitor comprising the steps of:
(1) Carrying out nucleophilic substitution reaction on alkaloid and 4-bromomethyl benzoate or 4-bromomethyl cinnamate under alkaline conditions to obtain an intermediate;
(2) The intermediate and aqueous solution of hydroxylamine undergo hydroxylamine hydrolysis under alkaline conditions to obtain the HDAC6 inhibitor.
In step (1), the alkaline conditions are provided by potassium carbonate and/or sodium carbonate.
In step (2), the alkaline conditions are provided by sodium hydroxide and/or potassium hydroxide.
When the structure of the HDAC6 inhibitor is a compound of formula I, the specific steps are:
(S1) carrying out nucleophilic substitution reaction on alkaloid and 4-bromomethyl benzoate under alkaline conditions to obtain an intermediate A;
(S2) obtaining a compound of the formula I through hydroxylamine hydrolysis reaction of an intermediate A and an aqueous solution of hydroxylamine under alkaline conditions;
In the step (S1), the molar ratio of the alkaloid to the methyl 4-bromomethylbenzoate is 1: (1-2);
In the step (S2), the molar ratio of the intermediate a to the aqueous solution of hydroxylamine is 1: (15-20).
A pharmaceutical composition comprising the HDAC6 inhibitor.
The use of said HDAC6 inhibitors in the manufacture of a medicament for the treatment of inflammatory and ulcerative colitis.
The beneficial effects of the invention are as follows:
The application provides an HDAC6 inhibitor, which is characterized in that an alkaloid structure with anti-inflammatory activity is connected with a hydroxamic acid group of the HDAC6 inhibitor to develop a series of novel compounds with the alkaloid structure and anti-ulcerative colitis activity, experimental data show that the compounds have better inhibition effect on the HDAC6 at enzyme level, and can be used for preparing medicines for preventing or treating ulcerative colitis. This is because the present inventors have found in long-term studies that alkaloids can reduce oxidative stress, reduce inflammatory mediators and MPO activity, maintain intestinal mucosa integrity, and alter inflammatory responses by inhibiting activation of inflammatory signaling pathways such as (NF- κb/Nrf 2). The alkaloid compounds have the effect of relieving or treating ulcerative colitis, and the mechanism of the alkaloid compounds is related to regulating immune inflammatory response, regulating intestinal flora and protecting intestinal mucosa barrier. Therefore, the application connects the alkaloid structure with anti-inflammatory activity with the hydroxamic acid group of the HDAC6 inhibitor through the design of computer-aided drugs and the framework transition principle, and obtains the HDAC6 inhibitor with anti-ulcerative colitis activity containing the alkaloid structure.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
Figure 1 shows the index of mice model of DSS-induced ulcerative colitis. Wherein A: rate of change of body weight of mice; b: disease activity index; c: a plot of colon length change in mice; all data are expressed as mean±sd with 6 mice per group. * P < 0.001 and P < 0.0001 represent a comparison to the Model group. # # P < 0.0001, representing a comparison to Normal group;
Figures 2A-F show H & E staining patterns of colon tissue ex vivo for a mouse model of DSS-induced ulcerative colitis.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, based on the examples herein, which are within the scope of the invention as defined by the claims, will be within the scope of the invention as defined by the claims.
The following describes the above technical scheme in detail with reference to specific embodiments.
The experimental methods used in the following examples are conventional methods unless otherwise specified. Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
Example 1
The present example provides an HDAC6 inhibitor ,N-hydroxy-4-(((1R,5S)-8-oxo-1,5,6,8-tetrahydro-2H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(4H)-yl)methyl)benzamide(AK-01), having the following structural formula:
the synthesis procedure of the above HDAC6 inhibitor is specifically as follows:
(1) 2mmol of cytisine and 3mmol of methyl 4-bromomethylbenzoate were weighed and mixed and added to 20mL of N, N-dimethylformamide, followed by addition of 4mmol of anhydrous potassium carbonate and stirring at room temperature for 3 hours. After TLC monitoring the reaction was completed, the reaction was extracted with water, concentrated under reduced pressure, and separated by thin layer preparative chromatography (developer PE/ea=1/1), and dried to give intermediate a.
(2) 2Mmol of intermediate A was dissolved in 15mL of methanol, 2mmol of sodium hydroxide was added and stirred at 0deg.C for 15 minutes, and 2mL of aqueous hydroxylamine solution was added dropwise. TLC was monitored until the reaction was complete, pH was adjusted to 7-8 with addition of hydrochloric acid, concentrated under reduced pressure, and purified by preparative thin layer chromatography (DCM/meoh=7/1) to give the title compound after drying in vacuo.
Light brown solid, yield :68%.m.p:82.6-83.7;1H NMR(400MHz,DMSO)δ11.14(s,1H),8.99(s,1H),7.58(d,J=7.8Hz,2H),7.35(dd,J=8.9,6.7Hz,1H),7.01(d,J=7.9Hz,2H),6.28(d,J=8.8Hz,1H),6.03(d,J=6.6Hz,1H),3.87(d,J=15.2Hz,1H),3.70(dd,J=15.3,6.3Hz,1H),3.46(dd,J=35.6,14.3Hz,2H),3.01(s,1H),2.88(d,J=10.5Hz,1H),2.73(d,J=10.4Hz,1H),2.39(s,1H),2.31(dd,J=23.9,10.5Hz,2H),1.84(d,J=12.6Hz,1H),1.76-1.66(m,1H).
HRMS (ESI) C 19H21N3O3[M+H]+ found 340.1662 and 340.1663.
Example 2
This example provides another HDAC6 inhibitor, 4- ((3, 4-dihydroisoquinolin-2 (1H) -yl) methyl) -N-hydroxybenzamide (AK-03), having the structural formula:
The synthesis procedure is as in example 1, except that cytisine is replaced by 1,2,3, 4-tetrahydroisoquinoline.
Pale pink solid, yield :66%.m.p:176.9-177.8;1H NMR(400MHz,DMSO)δ7.73(d,J=7.4Hz,2H),7.42(d,J=7.3Hz,2H),7.13-7.04(m,3H),6.98(d,J=6.7Hz,1H),3.67(s,2H),3.53(s,2H),2.80(t,J=5.7Hz,2H),2.66(t,J=5.7Hz,2H).13C NMR(101MHz,DMSO-d6)δ142.22,135.16,134.51,129.03,128.93,127.34,126.81,126.47,125.95,61.86,55.89,50.73,29.14.
HRMS (ESI) C 17H18N2O2[M+H]+ found 283.1447 and 283.1453.
Example 3
This example provides another HDAC6 inhibitor, 4- (6, 7-dimethoxy-3,4-dihydroisoquinolin-2 (1H) -yl) methyl) -N-hydroxybenzamide (AK-05), having the structure:
the synthesis procedure was as in example 1, except that cytisine was replaced with 6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinoline.
Pale pink solid, yield :65%.m.p:108.5-110.2;1H NMR(400MHz,DMSO)δ7.72(d,J=7.8Hz,2H),7.41(d,J=7.8Hz,2H),6.65(s,1H),6.56(s,1H),3.68(s,3H),3.65(s,5H),3.42(s,2H),2.72(t,J=5.8Hz,2H),2.64(t,J=5.8Hz,2H).13C NMR(101MHz,DMSO-d6)δ147.62,147.38,142.25,132.09,129.06,127.31,126.88,126.18,112.25,110.36,61.94,55.92,55.91,55.48,51.01,28.73,26.81.
HRMS (ESI) C 19H22N2O4[M+H]+ found 343.1659 and 343.1665.
Example 4
This example provides another HDAC6 inhibitor, N-hydroxy-4- ((1, 3,4, 9-tetrahydroo-2H-pyrido [3,4-b ] indol-2-yl) methyl) benzamide (AK-07), having the structure shown below:
The procedure is as in example 1, except that cytisine is replaced by 1,2,3, 4-tetrahydro-9H-pyrido [3,4-B ] indole.
Light brown solid, yield :70%.m.p:147.2-148.3;1H NMR(400MHz,DMSO)δ7.73(d,J=7.7Hz,2H),7.44(d,J=7.7Hz,2H),7.35(d,J=7.7Hz,1H),7.24(d,J=7.9Hz,1H),6.99(t,J=7.4Hz,1H),6.93(t,J=7.3Hz,1H),3.76(s,2H),3.56(s,2H),2.80(t,J=5.6Hz,2H),2.69(t,J=5.6Hz,2H).
HRMS (ESI) C 19H19N3O2[M+H]+ found 322.1556 and 322.1553.
Example 5
This example provides another HDAC6 inhibitor, N-hydroxy-4- (2-oxo-3, 4-dihydroquinolin-1 (2H) -yl) methyl) benzamide (AK-09), having the following structural formula:
The synthesis procedure is as in example 1, except that cytisine is replaced by 2-hydroxyquinoline.
Light brown solid, yield :68%.m.p:115.0-116.8;1H NMR(400MHz,DMSO)δ7.67(d,J=7.7Hz,2H),7.28(d,J=7.7Hz,2H),7.22(d,J=7.1Hz,1H),7.10(t,J=7.6Hz,1H),6.95(t,J=7.2Hz,1H),6.86(d,J=7.9Hz,1H),5.17(s,2H),2.94(t,J=7.0Hz,2H),2.70(dd,J=8.4,5.8Hz,2H).
HRMS (ESI) C 17H16N2O3[M+Na]+ found 319.1059 and 319.1063.
Example 6
This example provides another HDAC6 inhibitor, N-hydroxy-4- (2-oxoquinoxalin-1 (2H) -yl) methyl) benzamide (AK-11), having the structural formula:
The synthesis procedure is as in example 1, except that cytisine is replaced by 2-hydroxyquinoxaline.
Pale pink solid, yield :60%.m.p:181.5-183.3;1H NMR(400MHz,DMSO)δ8.36(s,1H),7.86(d,J=7.5Hz,1H),7.68(d,J=7.4Hz,2H),7.55(t,J=7.5Hz,1H),7.42(d,J=7.9Hz,1H),7.35(dd,J=14.5,7.3Hz,3H),5.74(s,1H),5.52(s,2H).13C NMR(101MHz,DMSO-d6)δ164.27,154.97,150.84,139.29,133.46,132.66,132.46,131.56,130.35,127.78,127.25,124.18,115.59,44.79.
HRMS (ESI) C 16H13N3O3[M+Na]+ found 318.0855 and 318.0854.
Example 7
This example provides another HDAC6 inhibitor, 4- ((1H-indol-yl) amino) methyl) -N-hydroxybenzamide (AK-13), having the structural formula:
the synthesis procedure is as in example 1, except that cytisine is replaced by 5-aminoindole.
Brown solid, yield :50%.m.p:185.2-186.8;1H NMR(400MHz,DMSO)δ10.62(s,1H),7.68(d,J=7.8Hz,2H),7.44(d,J=7.8Hz,2H),7.10(d,J=8.4Hz,2H),6.57(dd,J=8.0,2.8Hz,1H),6.52(d,J=6.9Hz,1H),6.10(t,J=3.8Hz,1H),5.69(s,1H),4.29(s,2H).13C NMR(101MHz,DMSO-d6)δ145.04,142.33,131.50,130.06,128.80,127.52,127.26,125.14,112.17,111.76,101.04,100.43,47.88.
HRMS (ESI) C 16H15N3O2[M+H]+ found 282.1243 and 282.1251.
Example 8
This example provides another HDAC6 inhibitor ,(E)-N-hydroxy-3-(4-((1R,5S)-8-oxo-1,5,6,8-tetrahydro-2H-1,5-methanopyrido-[1,2-a][1,5]diazocin-3(4H)-yl)methyl)phenyl)acrylamide(AK-02), having the following structural formula:
the synthesis procedure of the above HDAC6 inhibitor is specifically as follows:
(1) 2mmol of cytisine and 3mmol of methyl 4-bromomethylcinnamate were weighed and mixed and added to 20mL of N, N-dimethylformamide, followed by addition of 4mmol of anhydrous potassium carbonate and stirring at room temperature for 3 hours. After TLC monitoring the reaction was completed, the reaction was extracted with water, concentrated under reduced pressure, and separated by thin layer preparative chromatography (developer PE/ea=1/1), and dried to give intermediate B.
(2) 2Mmol of intermediate B was dissolved in 15mL of methanol, 2mmol of sodium hydroxide was added and stirred at 0deg.C for 15 minutes, and 2mL of aqueous hydroxylamine solution was added dropwise. TLC was monitored until the reaction was complete, pH was adjusted to 7-8 with addition of hydrochloric acid, concentrated under reduced pressure, and purified by preparative thin layer chromatography (DCM/meoh=7/1) to give the title compound after drying in vacuo.
Pale pink solid, yield :71%.m.p:157.5-159.1;1H NMR(400MHz,DMSO)δ7.59-7.23(m,4H),6.99(d,J=7.5Hz,2H),6.41(d,J=15.7Hz,1H),6.27(d,J=8.8Hz,1H),6.03(d,J=6.6Hz,1H),3.86(d,J=15.3Hz,1H),3.70(dd,J=15.3,6.3Hz,1H),3.47(d,J=14.2Hz,2H),3.01(s,1H),2.88(d,J=10.6Hz,1H),2.74(d,J=10.4Hz,1H),2.39(s,1H),2.29(dd,J=16.8,10.6Hz,2H),1.84(d,J=12.6Hz,1H),1.71(d,J=12.7Hz,1H).13C NMR(101MHz,DMSO-d6)δ163.20,162.69,152.51,140.30,139.24,138.19,133.96,128.86,127.66,119.21,115.72,104.34,61.20,60.14,59.97,50.09,35.02,27.89,25.62.
HRMS (ESI) C 21H23N3O3[M+H]+ found 366.1818 and 366.1815.
Example 9
This example provides another HDAC6 inhibitor, (E) -3- (4- ((3, 4-dihydroisoquinolin-2 (1H) -yl) methyl) phenyl) -N-hydroxyacrylamide (AK-04) having the structure:
The synthesis procedure is as in example 8, except that cytisine is replaced by 1,2,3, 4-tetrahydroisoquinoline.
Pale pink solid, yield :60%.m.p:185.0-186.9;1H NMR(400MHz,DMSO)δ10.63(s,1H),7.53(d,J=7.5Hz,1H),7.41(d,J=7.2Hz,2H),7.34(d,J=7.7Hz,1H),7.24(d,J=8.0Hz,1H),6.96(dt,J=25.9,7.3Hz,2H),6.46(d,J=15.8Hz,1H),3.74(s,2H),3.55(s,2H),2.80(t,J=5.6Hz,2H),2.69(t,J=5.6Hz,2H).13C NMR(101MHz,DMSO-d6)δ163.24,140.51,138.55,135.19,134.53,134.10,129.69,128.92,127.93,126.82,126.45,125.94,119.15,61.94,55.89,50.71,29.14.
HRMS (ESI) C 19H20N2O2[M+H]+ found 390.1604 and 309.1608.
Example 10
This example provides another HDAC6 inhibitor ,(E)-3-(4-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)phenyl)-N-hydroxyacrylamide(AK-06), having the structure shown below:
the procedure is as in example 8, except that cytisine is replaced by 6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinoline.
Light brown solid, yield :58%.m.p:119.4-120.6;1H NMR(400MHz,DMSO)δ7.51(d,J=7.5Hz,2H),7.43(d,J=14.9Hz,1H),7.37(d,J=7.4Hz,2H),6.64(s,1H),6.56(s,1H),6.52-6.23(m,1H),3.68(s,3H),3.64(s,3H),3.61(s,2H),3.41(s,2H),2.71(t,J=5.6Hz,2H),2.63(t,J=5.7Hz,2H).13C NMR(101MHz,DMSO-d6)δ147.62,147.38,134.15,129.72,127.89,126.92,126.20,112.24,110.36,62.04,55.92,55.89,55.49,55.36,51.00,28.75.
HRMS (ESI) C 21H24N2O4[M+H]+ found 369.1815 and 369.1822.
Example 11
This example provides another HDAC6 inhibitor ,(E)-N-hydroxy-3-(4-((1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)methyl)-phenyl)acrylamide(AK-08), having the structure shown below:
the procedure is as in example 8, except that cytisine is replaced by 1,2,3, 4-tetrahydro-9H-pyrido [3,4-B ] indole.
Light brown solid, yield :80%.m.p:145.6-146.3;1H NMR(400MHz,DMSO-d6)δ10.63(s,1H),7.53(d,J=7.5Hz,2H),7.42(t,J=10.1Hz,3H),7.34(d,J=7.7Hz,1H),7.24(d,J=8.0Hz,1H),6.99(t,J=7.4Hz,1H),6.92(t,J=7.3Hz,1H),6.46(d,J=15.7Hz,1H),3.74(s,2H),3.55(s,2H),2.80(t,J=5.6Hz,2H),2.70(d,J=5.4Hz,2H).13C NMR(101MHz,DMSO-d6)δ140.80,136.30,134.14,133.19,129.74,127.94,127.16,120.78,119.13,118.74,117.81,111.34,106.79,61.42,51.11,50.37,21.61.
HRMS (ESI) C 21H21N3O2[M+H]+ found 348.1713 and 348.1713.
Example 12
This example provides another HDAC6 inhibitor, (E) -N-hydroxy-3- (4- (2-oxoquinoxalin-1 (2H) -yl) methyl) phenyl) acrylic amide (AK-10) having the structure shown below:
The synthesis procedure is as in example 8, except that cytisine is replaced by 2-hydroxyquinoxaline.
Pale pink solid, yield :66%.m.p:146.2-147.7;1H NMR(400MHz,DMSO)δ8.36(s,1H),7.86(d,J=7.8Hz,1H),7.56(t,J=7.6Hz,1H),7.50(d,J=7.8Hz,2H),7.42(d,J=9.5Hz,1H),7.39-7.35(m,1H),7.30(d,J=7.7Hz,2H),6.41(d,J=15.8Hz,1H),5.50(s,2H),4.34(t,J=5.2Hz,1H).
HRMS (ESI) C 18H15N3O3[M+Na]+ found 344.1011 and 344.1009.
Example 13
This example provides another HDAC6 inhibitor, (E) -N-hydroxy-3- (4- (indolin-1-ylmethyl) phenyl) acrylic amide (AK-12) having the structure shown below:
The procedure is as in example 8, except that cytisine is replaced by indoline.
Dark brown solid, yield :40%.m.p:104.8-105.1;1H NMR(400MHz,DMSO-d6)δ7.52(s,2H),7.39(t,J=12.0Hz,3H),7.08-6.93(m,2H),6.57(q,J=7.2Hz,3H),4.26(s,2H),3.24(d,J=8.1Hz,2H),2.88(t,J=8.1Hz,2H).
HRMS (ESI) C 18H18N2O2[M+H]+ found 295.1447 and 295.1446.
Example 14
This example provides another HDAC6 inhibitor, N-hydroxy-4- ((9-oxoacridin-10 (9H) -yl) methyl) benzamide (AK-14), having the structure shown below:
the synthesis procedure of the above HDAC6 inhibitor is specifically as follows:
(1) 2mmol of acridone is weighed, added into 10mL of N, N-dimethylformamide for dissolution, then 3mmol of sodium hydride is added, stirring is carried out for 10 minutes at 0 ℃, 3mmol of methyl 4-bromomethylbenzoate is added, the temperature is gradually raised to room temperature, and stirring is carried out for 2 hours. After TLC monitoring to completion of the reaction, the reaction was quenched, extracted, concentrated under reduced pressure, and separated by thin layer preparative chromatography (developing solvent PE/ea=1/1) to give intermediate C after drying.
(2) 2Mmol of intermediate C was dissolved in 15mL of methanol, 2mmol of sodium hydroxide was added and stirred at 0deg.C for 15 minutes, and 2mL of aqueous hydroxylamine solution was added dropwise. TLC was monitored until the reaction was complete, pH was adjusted to 7-8 with addition of hydrochloric acid, concentrated under reduced pressure, and purified by preparative thin layer chromatography (DCM/meoh=7/1) to give the title compound after drying in vacuo.
Pale yellow solid, yield :80%.m.p:226.9-227.8;1H NMR(400MHz,DMSO)δ11.15(s,1H),9.09(s,1H),8.40(d,J=7.8Hz,2H),7.93-7.67(m,4H),7.63(d,J=8.6Hz,2H),7.36(t,J=7.4Hz,2H),7.23(d,J=7.8Hz,2H),5.84(s,2H).13C NMR(101MHz,DMSO-d6)δ177.18,142.53,140.07,134.84,132.46,127.98,127.23,126.34,122.20,122.12,116.58,49.35.
HRMS (ESI) C 21H16N2O3[M+Na]+ found 367.1059 and 367.1061.
Experimental example 1
Inhibition of HDAC1 and HDAC6 enzymes by 14 compounds at 50nM concentration was screened in vitro using fluorescence, with SAHA as positive compound, as follows:
(1) Preparing 1x assay buffer (modified Tris buffer);
(2) Compound serial dilutions compounds were transferred to assay plates with Echo in 100% dmso. The final fraction of dimethyl sulfoxide was 1%;
(3) Preparing enzyme solution, namely preparing the enzyme solution in a 1x experiment buffer solution;
(4) Preparing a substrate solution by adding trypsin and ac peptide substrate into a 1x experiment buffer solution to prepare a substrate solution;
(5) Transfer 15 μl of enzyme solution to assay plate, or low control transfer 15 μl of 1x assay buffer;
(6) Incubating for 15 minutes at room temperature;
(7) 10 mu L of substrate solution is added to each well to start the reaction;
(8) Dynamically reading the plate on Envision, wherein the excitation wavelength is 355nm, and the emission wavelength is 460nm;
(9) Curve fitting the data was fitted in Excel and inhibition values were obtained using equation (1).
Formula (1): inh% = (Max-Signal)/(Max-Min) 100
The data were Fit in xml-Fit and IC50 values were obtained using equation (2).
Equation (2) y=bottom+ (Top-Bottom)/(1+ (IC 50/X) HillSlope) Y is the inhibition and X is the recombination concentration.
TABLE 1 in vitro HDAC1 and HDAC6 enzyme inhibitory Activity
/>
As can be seen from Table 1, all of the 14 compounds synthesized from formulas I-II (i.e., containing N-hydroxycinnamamide groups) showed potent inhibitory activity against HDAC1 and HDAC6 at a concentration of 50nM, except AK-12. Of the compounds synthesized from formula I (i.e., containing N-hydroxy-4-methylbenzamide groups), AK-11, AK-13 and AK-14 exhibited strong HDAC6 inhibitory activity, among which it is presumed that the HDAC1/6 subtype of AK-14 has the best selectivity.
Experimental example 2
The inhibition rate of NO production of the 14 compounds on the mouse macrophage RAW264.7 was determined by MTT method, and the result is shown in Table 2 by taking dexamethasone as a positive control.
RAW264.7 cells were incubated in DMEM medium, 10% fetal bovine serum (Biological Industries), 100U/mL penicillin and 100mg/mL streptomycin (Beyotime) were added, transferred to 37℃and cultured in a humidified environment with 5% CO 2.
Log-grown RAW264.7 cells were collected in 15mL centrifuge tubes, centrifuged at 800rpm for 5min, the supernatant discarded, and diluted to the appropriate density with fresh medium for use. A special cover slip was placed in the center of the cell counter plate, 10. Mu.L of suspension was aspirated from the centrifuge tube, and added between the counter plate and the special cover slip, and the cover slip was filled with liquid by siphoning. The counting plate was placed under a microscope for counting.
The counting formula: (number of cells per well×100×96 well plates)/(number of 4 large cells×10 4) =suspension volume (mL)
The cell suspension volume was calculated and by calculating the cell suspension density, 8000-12000 cells per well were plated, i.e.: a 96-well plate was plated to aspirate cell suspension volume (mL) = (number of cells per well×96×1)/cell suspension density. The desired cell suspension and culture medium were mixed well, and the suspension was applied to a 96-well plate using a discharge gun at 100. Mu.L per well, and the cell suspension was mixed once every three times. After the cell suspension was added, the plate was covered and the cell density and uniformity were observed under an inverted microscope.
In 96-well plates, the experimental groups were treated by adding different compounds for 48 hours, 3 wells as blank groups, an equal volume of DMSO,3 wells as LPS groups, 100 μl of medium per well, and no drug addition at the side wells. After 48h, each group of cell suspensions was transferred to a new cell counting plate, and then solution A and solution B in the NO kit were added to each well, respectively, after the solution was changed from colorless to pink, the culture solution was collected, the nitrite level (index of NO production) was measured by Griess method, and the absorbance (OD 540) of the sample was measured at 540nm wavelength by an enzyme-labeled analyzer.
Control, DMSO solution treated with LPS only;
compound, LPS and Compound treated solution;
blanc-DMSO solution without LPS.
Table 2-inhibitory Activity of Compounds on NO production by mouse macrophage RAW264.7
/>
As can be seen from Table 2, the 14 compounds AK-04, AK-06, AK-08 and AK-14 showed good inhibitory activity (inhibition ratio is more than 50%) on the NO production of mouse macrophage RAW264.7 at the concentrations of 5. Mu.M and 10. Mu.M, and were similar to dexamethasone as a positive drug.
Experimental example 3
In vivo animal experimental study on the therapeutic effect of compound AK-14 on mice model of DSS induced ulcerative colitis shows the results in FIG. 1 and FIG. 2. The results show that: the compound AK-14 has good treatment effect on the ulcerative colitis induced by DSS, 15mg/kg or 30mg/kg of administration can obviously reduce the influence of the disease on the weight of mice (figure 1A), the disease activity index can also obviously reduce (figure 1B), compared with a DSS modeling group, the colon length of AK-14 treatment group mice is longer (figure 1C), no obvious ulcer and inflammatory cell infiltration are seen in the colon (figure 2), and the effect is superior to that of a positive drug Tofacitinib. Thus, compound AK-14 is considered to have a good therapeutic effect on DSS-induced ulcerative colitis in mice.
(1) Animal modeling and index evaluation method
C57BL/6J mice were randomly divided into a normal group, a DSS model group, and an experimental group (4 experimental groups are AK-1415mg/kg, AK-1430mg/kg, respectively) and a positive drug group (Tofacitinib 40 mg/kg) according to body weight. On day 1, each group was free to drink 2.5% aqueous DSS solution except the normal group, and the normal control group was given sterile water without DSS, and after 6 days of continuous drinking, molding was successful. All mice were changed to sterilized water without DSS on day seven and dosing was started, with 4 experimental groups each being given by intraperitoneal injection and the positive group (Tofacitinib) by gavage, for 6 consecutive days, 1 time per day.
From the modeling, the eating, activity and hair conditions of the mice were observed daily, the body weight was weighed, and the presence or absence of hematochezia and the like of the mice were observed, so as to evaluate the degree of colitis disease. The severity of the disease was quantified by a disease activity index (DISEASE ACTIVITY index, DAI), which was comprehensively evaluated by weight loss, stool shape and rectal bleeding, and specific indices are shown in table 3. The corresponding compound medicines are orally taken by the treatment group. On day 8 of dosing, all experimental mice were sacrificed, the free colon and distal ileum of each mouse were taken, the general changes in the colon of each group of mice were observed, the entire colon and rectal length were measured, the intestinal contents were removed, and the intestinal contents were removed, rinsed with normal saline, and fixed as specimens with 10% formalin solution. Tissue specimens were taken for visual and histopathological examination.
TABLE 3 evaluation index of Disease Activity Index (DAI)
(2) Mouse colon tissue section and analysis method
Drawing materials: fresh tissue is fixed for more than 24 hours by using a fixing liquid. And taking out the tissue from the fixing solution, trimming the tissue of the target part in a fume hood by using a surgical knife, and placing the trimmed tissue and a corresponding label in a dehydration box.
Dehydrating: and placing the dehydration box into a basket, and sequentially carrying out gradient alcohol dehydration in a dehydrator. 75% alcohol 4h-85% alcohol 2h-90% alcohol 2h-95% alcohol 1 h-absolute alcohol I30 min-absolute alcohol II 30 min-alcohol benzene 5-10 min-xylene I5-10 min-xylene II 5-10 min-wax I1 h-wax II 1 h-wax III 1h.
Embedding: embedding the wax-soaked tissue in an embedding machine. Firstly, putting melted wax into an embedding frame, taking out tissues from a dehydration box before the wax is solidified, putting the tissues into the embedding frame according to the requirement of an embedding surface, and attaching corresponding labels. Cooling at-20 deg.c, solidifying, taking out the wax block from embedding frame and trimming.
Slicing: the trimmed wax block was sliced in a paraffin slicer to a thickness of 3 μm. The slices float on warm water at 40 ℃ of a slice spreading machine to flatten the tissues, the glass slide drags the tissues out, and the slices are baked in a baking oven at 60 ℃. And (5) baking the water, drying the wax, baking, taking out and preserving at normal temperature for standby.
Paraffin sections dewaxed to water: sequentially placing the slices into xylene I20 min-xylene II 20 min-absolute ethanol I5 min-absolute ethanol II 5min-75% ethanol 5min, and washing with tap water.
Hematoxylin staining: hematoxylin dyeing for 3-5min, hydrochloric acid aqueous solution differentiation, ammonia aqueous solution blue returning and water washing;
eosin staining: the slices are dehydrated in gradient alcohol of 85% and 95% in sequence and then are dyed in eosin dye solution for 5min.
And (3) removing the water sealing piece: sequentially slicing, adding absolute ethyl alcohol I5 min-absolute ethyl alcohol II 5 min-absolute ethyl alcohol III 5 min-dimethyl I5 min-dimethyl II 5min, and sealing with neutral resin.
Photographing: an optical microscope was used to collect images (microscope: NIKON ECLIPSE CI, imaging system: NIKON DIGITAL SIGHT DS-FI2, MADE IN JAPAN, magnification of film: 100X 200X).
The foregoing is merely illustrative of the present invention, and the present invention is not limited thereto, and any person skilled in the art will readily recognize that variations or substitutions are within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (10)
1. An HDAC6 inhibitor characterized by the structure:
R is at least one substituent selected from cytisine, acridone, indoline, 1,2,3, 4-tetrahydro-9H-pyridine [3,4-B ] benzidine, 1,2,3, 4-tetrahydroisoquinoline, 6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinoline, 5-aminoindole, 2-hydroxyquinoxaline, 2-hydroxyquinoline and the like;
x is a saturated or unsaturated alkane containing from 0 to 4 carbon atoms.
2. The HDAC6 inhibitor according to claim 1, having the structure of formula I or formula II, in particular:
wherein R1 and R2 are respectively and independently selected from at least one of cytisine, acridone, indoline, 1,2,3, 4-tetrahydro-9H-pyridine [3,4-B ] indole, 1,2,3, 4-tetrahydroisoquinoline, 6, 7-dimethoxy-1, 2,3, 4-tetrahydroisoquinoline, 5-aminoindole, 2-hydroxyquinoxaline and 2-hydroxyquinoline.
3. The HDAC6 inhibitor according to claim 1, characterized by any one of the following structures:
4. The method of preparing an HDAC6 inhibitor according to claim 1, comprising the steps of:
(1) Carrying out nucleophilic substitution reaction on alkaloid and 4-bromomethyl benzoate or 4-bromomethyl cinnamate under alkaline conditions to obtain an intermediate;
(2) The intermediate and aqueous solution of hydroxylamine undergo hydroxylamine hydrolysis under alkaline conditions to obtain the HDAC6 inhibitor.
5. The method of preparing an HDAC6 inhibitor according to claim 4, wherein in step (1), the alkaline condition is provided by potassium carbonate and/or sodium carbonate.
6. The method of preparing an HDAC6 inhibitor according to claim 4, wherein in step (2), the alkaline condition is provided by sodium hydroxide and/or potassium hydroxide.
7. The method of preparing an HDAC6 inhibitor according to claim 4, wherein when the HDAC6 inhibitor has the structure of a compound of formula I, the specific steps are:
(S1) carrying out nucleophilic substitution reaction on alkaloid and 4-bromomethyl benzoate under alkaline conditions to obtain an intermediate A;
(S2) obtaining a compound of the formula I through hydroxylamine hydrolysis reaction of an intermediate A and an aqueous solution of hydroxylamine under alkaline conditions;
8. The method of preparing an HDAC6 inhibitor according to claim 7, wherein in step (S1), the molar ratio of the alkaloid to methyl 4-bromomethylbenzoate is 1: (1-2);
In the step (S2), the molar ratio of the intermediate a to the aqueous solution of hydroxylamine is 1: (15-20).
9. A pharmaceutical composition comprising the HDAC6 inhibitor of any one of claims 1-6.
10. Use of an HDAC6 inhibitor according to any one of claims 1 to 6 for the manufacture of a medicament for the treatment of inflammatory and ulcerative colitis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410113655.3A CN118027033A (en) | 2024-01-26 | 2024-01-26 | HDAC6 inhibitor, preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410113655.3A CN118027033A (en) | 2024-01-26 | 2024-01-26 | HDAC6 inhibitor, preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118027033A true CN118027033A (en) | 2024-05-14 |
Family
ID=90998388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410113655.3A Pending CN118027033A (en) | 2024-01-26 | 2024-01-26 | HDAC6 inhibitor, preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118027033A (en) |
-
2024
- 2024-01-26 CN CN202410113655.3A patent/CN118027033A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102666727B1 (en) | Aromatic vinyl or aromatic ethyl derivatives, manufacturing methods, intermediates, drug compositions and uses thereof | |
CN108516958B (en) | Fused ring derivative, preparation method, intermediate, pharmaceutical composition and application thereof | |
KR20210089195A (en) | Biphenyl-based compounds, intermediates thereof, preparation methods, pharmaceutical compositions and uses | |
MXPA06001739A (en) | Substituted arylalkanoic acid derivative and use thereof. | |
WO2007114213A1 (en) | Substituted bicyclic cyclic derivative and use thereof | |
LU86406A1 (en) | CARDIOTONIC ANTITHROMBOGENIC IMIDAZOQUINOLEINS | |
JP4256166B2 (en) | Carboxylic acid compound | |
CN106432229B (en) | One kind is used for the compound for treating or preventing hyperuricemia or gout | |
CA2831716C (en) | Pyrido[3,4-b]indolyl compounds for treatment of metabolic syndrome | |
CN108863976B (en) | Compounds useful as IDO modulators and uses thereof | |
CN104755077A (en) | Composition for preventing or treating kidney disease comprising pyrazole derivative | |
CN114667289A (en) | Heteroaryl plasma kallikrein inhibitors | |
CN110354110A (en) | A kind of Fatty synthesis enzyme inhibitor and its application | |
CN107115344B (en) | Tyrosine kinase inhibitor is preparing the purposes in the drug for preventing and/or treating fibrotic disease | |
CN118027033A (en) | HDAC6 inhibitor, preparation method thereof and application thereof in anti-inflammatory and ulcerative colitis | |
SU1199197A3 (en) | Method of producing phenylalkannic acid | |
CN111454229A (en) | Dihydronaphthoisoxazole derivative and application thereof in antitumor drugs | |
WO2018101329A1 (en) | Novel ester compound and pin1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | |
WO2003053976A1 (en) | PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR | |
CN101735222B (en) | Pyrrole-nitrogen heterocyclic tropone compound and application thereof as protein-tyrosine-phosphatase 1 B inhibitor | |
WO2020147803A1 (en) | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-α]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | |
CN118084898B (en) | ICRT14 derivative, preparation method and application thereof | |
KR101137168B1 (en) | Pyrrolo[2,3-d]pyridazine derivatives and processes for the preparation thereof | |
CA2419838A1 (en) | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | |
CN108503634A (en) | 1H- [1,2,3] triazole simultaneously [4,5-c] quinoline and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |